Splenic marginal zone lymphoma laboratory findings: Difference between revisions

Jump to navigation Jump to search
(Mahshid)
Line 5: Line 5:
Laboratory tests for splenic marginal zone lymphoma include [[complete blood count]] (CBC), blood chemistry studies, [[cytogenetic analysis]], [[flow cytometry]], [[immunohistochemistry]], [[genetic testing]], [[FISH]], [[PCR]], and [[immunophenotyping]].
Laboratory tests for splenic marginal zone lymphoma include [[complete blood count]] (CBC), blood chemistry studies, [[cytogenetic analysis]], [[flow cytometry]], [[immunohistochemistry]], [[genetic testing]], [[FISH]], [[PCR]], and [[immunophenotyping]].
==Laboratory tests==
==Laboratory tests==
Laboratory tests for splenic marginal zone lymphoma include:<ref name=”seer”>Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22,2015</ref>
Laboratory tests for [[splenic marginal zone lymphoma]] [[(SMZL)]] include:<ref name=”seer”>Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22,2015</ref>
* [[Complete blood count]] (CBC)
* [[Complete blood count]] (CBC) with differential count
:* [[Thrombocytopenia]]
** [[Pancytopenia]] or leukemic presentation with [[leukocytosis]], [[anemia]], [[thrombocytopenia]]<ref name="pmid23484698">{{cite journal |vauthors=Yang SM, Jiang Q, Jiang B, Chen DB, Wang J, Jiang H, Lu J, Lu XJ, Bao L, Shi HX, Liu YR, Huang XJ |title=[Clinical characteristics of splenic marginal zone lymphoma with abnormal complete blood count] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=21 |issue=1 |pages=87–94 |date=February 2013 |pmid=23484698 |doi=10.7534/j.issn.1009-2137.2013.01.019 |url=}}</ref>
:* [[Anaemia]]
* [[Serum albumin]] levels
* Peripheral Blood Smear
* serum [[LDH]] levels
:* Circulating [[lymphoma]] cells  show short villi at the poles of cells and plasmacytoid differentiation<ref name="mel1">  
* [[Beta-2- microglobulin]]
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3497180&query_hl=15&itool=pubmed_ExternalLink]
Melo JV, Hegde U, Parreira A, Thompson I, Lampert IA, Catovsky D. "Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens."
'''J Clin Pathol.''' 1987 Jun;40(6):642-51. PMID: 3497180</ref>
* Blood chemistry studies
* [[Cytogenetic analysis]]
* [[Flow cytometry]]
* [[Immunohistochemistry]]
* [[Immunohistochemistry]]
** Typically positive for [[CD20]],[[CD79a]], BCL-2 and [[immunoglobuin M]] ([[IgM]].
** Surface immunoglobulin D (IgD) and DBA44 are variably expressed.
** Negative for [[CD5]], [[CD10]], [[CD43]], [[CD103]], CD123, [[Annexin A1]], BCL-6 and LEF-1.
* [[Genetic testing]]
* [[Genetic testing]]
* [[FISH]] (fluorescence in situ hybridization)
* Chromosomal 7q32 deletion (30-40%).
* [[PCR]]  
* Chromosome 3q gains (20-30%)).
* [[Immunophenotyping]]
* NOTCH2 and KLF2 are the commonly reported gene mutations.
* [[Flow cytometry]]<ref name="pmid">{{cite journal |vauthors=Hu Y, Chen Y, Wang LH, Chen X, Fang F, Liu SQ, Wu XQ, Zhu P |title=[Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=22 |issue=2 |pages=349–56 |date=April 2014 |pmid= |doi=10.7534/j.issn.1009-2137.2014.02.016 |url=}}</ref>
* [[FISH]] ([[fluorescence in situ hybridization]])<ref name="pmid29228725">{{cite journal |vauthors=Yi S, Yan Y, Xiong W, Lv R, Yu Z, Liu W, Liu E, Li H, Liu H, Li Z, An G, Xu Y, Ru K, Zou D, Qiu L |title=Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region |journal=Oncotarget |volume=8 |issue=58 |pages=98757–98770 |date=November 2017 |pmid=29228725 |pmc=5716765 |doi=10.18632/oncotarget.21931 |url=}}</ref>
* [[PCR]]<ref name="pmid25612624">{{cite journal |vauthors=Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F |title=DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features |journal=Blood |volume=125 |issue=12 |pages=1922–31 |date=March 2015 |pmid=25612624 |pmc=4416938 |doi=10.1182/blood-2014-08-596247 |url=}}</ref>


==References==
==References==

Revision as of 22:44, 5 January 2019

Splenic marginal zone lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Splenic marginal zone lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Splenic marginal zone lymphoma laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Splenic marginal zone lymphoma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Splenic marginal zone lymphoma laboratory findings

CDC on Splenic marginal zone lymphoma laboratory findings

Splenic marginal zone lymphoma laboratory findings in the news

Blogs on Splenic marginal zone lymphoma laboratory findings

Directions to Hospitals Treating Splenic marginal zone lymphoma

Risk calculators and risk factors for Splenic marginal zone lymphoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Laboratory tests for splenic marginal zone lymphoma include complete blood count (CBC), blood chemistry studies, cytogenetic analysis, flow cytometry, immunohistochemistry, genetic testing, FISH, PCR, and immunophenotyping.

Laboratory tests

Laboratory tests for splenic marginal zone lymphoma (SMZL) include:[1]

References

  1. Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22,2015
  2. Yang SM, Jiang Q, Jiang B, Chen DB, Wang J, Jiang H, Lu J, Lu XJ, Bao L, Shi HX, Liu YR, Huang XJ (February 2013). "[Clinical characteristics of splenic marginal zone lymphoma with abnormal complete blood count]". Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 21 (1): 87–94. doi:10.7534/j.issn.1009-2137.2013.01.019. PMID 23484698.
  3. Hu Y, Chen Y, Wang LH, Chen X, Fang F, Liu SQ, Wu XQ, Zhu P (April 2014). "[Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry]". Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 22 (2): 349–56. doi:10.7534/j.issn.1009-2137.2014.02.016.
  4. Yi S, Yan Y, Xiong W, Lv R, Yu Z, Liu W, Liu E, Li H, Liu H, Li Z, An G, Xu Y, Ru K, Zou D, Qiu L (November 2017). "Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region". Oncotarget. 8 (58): 98757–98770. doi:10.18632/oncotarget.21931. PMC 5716765. PMID 29228725.
  5. Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F (March 2015). "DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features". Blood. 125 (12): 1922–31. doi:10.1182/blood-2014-08-596247. PMC 4416938. PMID 25612624.

Template:WH Template:WS